Unlisted Options Transactions, page-176

I wasn’t aware of that. I guess knockdown would have 0% FTO expression, whereas Zantrene as an FTO inhibitor would only reduce FTO expression - but to what extent?

correct me if I am wrong, but Zantrene appears to kick in as an FT0 inhibitor at low doses. So hopefully sufficient to produce similar effect as FTO knockdown.

thinking about it further, maybe FTO over expression is the real issue. So don’t need to knockdown FTO to have an impact but just regulate and restrict over expression.

long story short, agree it would be a shock if Zantrene as an inhibitor could not show similar benefits to Yang paper. Was cell lines, we are working with Melanoma and ccRCC wonder if that would make a difference?